➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Medtronic
McKesson
Harvard Business School
Baxter

Last Updated: April 15, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Ademetionine

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Ademetionine?

Ademetionine is an investigational drug.

There have been 7 clinical trials for Ademetionine. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2013.

The most common disease conditions in clinical trials are Drug-Induced Liver Injury, Hepatitis B, and Liver Diseases, Alcoholic. The leading clinical trial sponsors are Beijing 302 Hospital, ClinIntel, and MSI Methylation Sciences, Inc.

There is one US patent protecting this investigational drug and nineteen international patents.

Recent Clinical Trials for Ademetionine
TitleSponsorPhase
Glucocorticosteroid Therapy on Drug-induced Liver Injury: a Prospective Non-randomized Concurrent Control TrialLi YangPhase 4
36 Weeks Short-Term Optimization Treatment of Glucocorticosteroid in the Patients With Chronic Recurrent DILIBeijing 302 HospitalPhase 1/Phase 2
Efficacy and Safety of Glucocorticosteroid Treatment in the Patients With Chronic Recurrent DILIBeijing 302 HospitalPhase 1/Phase 2

See all Ademetionine clinical trials

Clinical Trial Summary for Ademetionine

Top disease conditions for Ademetionine
Top clinical trial sponsors for Ademetionine

See all Ademetionine clinical trials

US Patents for Ademetionine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ademetionine   Start Trial Method and culture medium for improving pluripotent stem cell differentiation inducing efficiency NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (Kumamoto, JP)   Start Trial
Ademetionine   Start Trial Indicator and analytics for sensor insertion in a continuous analyte monitoring system and related methods DexCom, Inc. (San Diego, CA)   Start Trial
Ademetionine   Start Trial RNA preparations comprising purified modified RNA for reprogramming cells THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (Philadelphia, PA)   Start Trial
Ademetionine   Start Trial Methanocarba derivatives of pseudoribose that inhibit adenosine kinase Legacy Emanuel Hospital & Health Center (Portland, OR) The United States of America, as represented by the Secretary, Department of Health and Human Services (Washington, DC)   Start Trial
Ademetionine   Start Trial Synthetic peptide amides and dimers thereof Cara Therapeutics, Inc. (Stamford, CT)   Start Trial
Ademetionine   Start Trial Benzylisoquinoline alkaloids (BIA) producing microbes, and methods of making and using the same THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (Stanford, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ademetionine

Drugname Country Document Number Estimated Expiration Related US Patent
Ademetionine European Patent Office EP2644694 2030-10-28   Start Trial
Ademetionine Japan JP5938726 2030-10-28   Start Trial
Ademetionine Japan JPWO2012056997 2030-10-28   Start Trial
Ademetionine World Intellectual Property Organization (WIPO) WO2012056997 2030-10-28   Start Trial
Ademetionine European Patent Office EP3068302 2033-11-14   Start Trial
Ademetionine World Intellectual Property Organization (WIPO) WO2015073588 2033-11-14   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Medtronic
McKesson
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.